Studying Circulating DNA to Detect Remaining Disease After Chemoradiotherapy in Advanced Head and Neck Cancer

What this Trial Is About

Researchers are evaluating circulating DNA as a biomarker to detect residual disease after chemoradiotherapy in patients with locally advanced head and neck squamous cell carcinoma. The main question is whether circulating DNA can identify remaining disease three months after treatment compared to clinical and radiological assessments. This ancillary trial is part of the larger Neck-TAR study. Participants will have blood samples collected at one and three months after completing chemoradiotherapy. These samples will be used to analyze circulating DNA levels and compare them to the objective response of the disease. The trial focuses on monitoring these biomarkers to better understand their potential role in detecting residual disease. During the study, participants will provide blood samples at the specified time points. Researchers will measure circulating DNA detection alongside clinical and radiological evaluations of disease response. The primary outcome is the detection of circulating DNA and its correlation with residual disease three months after treatment. Secondary outcomes include survival measures and genetic analyses from blood samples. The study runs until July 2031, providing long-term follow-up data.

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas